Alcea

Alcea is a Swiss biotechnology company dedicated to developing first-in-class, non-hormonal treatments for endometriosis and other women’s health conditions. Formerly known as FimmCyte, the company is a spin-off from the University of Zurich and ETH Zurich. Its lead program, FMC-101, is a monoclonal antibody that specifically targets and eliminates endometriotic lesions while sparing healthy tissue. By focusing on a disease-modifying approach rather than hormonal suppression, Alcea aims to provide a more effective and tolerable solution that preserves fertility for patients. The company is currently advancing its pipeline through IND-enabling studies and preparing for its first clinical trials. Alcea’s technology platform leverages unique insights into the molecular markers of gynecological diseases to create targeted biologics.